Braftovi or encorafenib is a prescription medication used to treat certain cancers that have spread (metastasized), cannot be removed with surgery, and have specific mutations in the BRAF gene. It is used in  to treat (a) Melanoma and Non-Small Cell Lung Cancer (NSCLC): In combination with Mektovi (binimetinib), encorafenib is used to treat adults with melanoma or NSCLC that has a BRAF mutation. (b) Colorectal Cancer (CRC): In combination with cetuximab and mFOLFOX6 (a chemotherapy regimen including fluorouracil, leucovorin, and oxaliplatin) to treat colorectal cancer.

The approval for this combination was based on response of the tumour and its duration. Ongoing studies are evaluating the clinical benefit of this regimen.
Encorafenib may also be used in combination with cetuximab alone for adults with colorectal cancer who have previously received treatment.
Encorafenib is advised against for the treatment of people whose melanoma, colorectal cancer, or NSCLC has wild-type BRAF (no BRAF mutation), due to insufficient studies. Your healthcare provider will perform a test to confirm if encorafenib or the combination with binimetinib is appropriate for your condition.

Encorafenib is a BRAF kinase inhibitor targeting mutated BRAF – BRAF V600E, wild-type BRAF, and CRAF, inhibiting tumor growth via the suppression of RAF/MEK/ERK pathway. It also binds other kinases at clinically relevant levels. In combination with binimetinib or cetuximab, it showed better anti-tumor effects and delayed resistance in BRAF-mutant models. Resistance in BRAF-mutant CRC due to EGFR activation can be overcome with EGFR-targeted combination therapy.

New primary malignancies, hemorrhage, uveitis and QT prolongation are the common side effects of encorafenib treatment. Breastfeeding is not recommended during treatment and for 2 weeks after. Encorafenib may impact and impair male fertility and reduce any effectiveness of hormonal contraceptives. Therefore, non-hormonal contraception is advised. Effective contraception used during and for 2 weeks after therapy.

In clinical trials, no significant effect of the product’s safety or effectiveness were seen in elderly patients. However, it is NOT approved for pediatric use. No dose adjustment is needed for mild to moderate renal or hepatic impairment, and use in severe impairment lacks dosing recommendations.

Pricing and availability: 

Encorafenib (Braftovi) is a targeted therapy designed for adults with melanoma, NSCLC, and colorectal cancer with a BRAF mutation that have spread or cannot be surgically removed. It aids in improving tumor response and the duration of benefit. When used in combination with binimetinib or cetuximab-based regimens, it offers a powerful, personalized treatment. It is not suitable for cancers without the BRAF mutation.

However, encorafenib is not registered in India and is not readily available through local pharmacies or standard distribution networks.

Since this is a prescription-only therapy, the price quotation for encorafenib is provided upon request, after submission of valid medical documents. For updated pricing and procurement details, contact us. 

The price of encorafenib in India may vary depending on market dynamics, supplier availability, and regulatory updates, since the drug is not registered for commercial sale in India. Cost also depends on supplier, origin country, shipping and documentation. For the most accurate and updated pricing in India, patients can contact us directly.
Pricing may also fluctuate due to GST/local taxes, exchange rates, and changes in company pricing policies.

We help patients buy encorafenib India safely and legally, ensuring full regulatory compliance under the Named Patient Supply (NPS) program and providing assistance throughout the process—from document verification to final delivery.

Access: 

As encorafenib is not commercially registered in India, it can only be accessed through the Named Patient Import Program (NPIP). We assist patients with products like encorafenib in India by procuring medicines for patients under the Named Patient Supply (NPS) route.

Braftovi or encorafenib is supplied as 75 mg capsules available in cartons containing two bottles of 90 capsules each and cartons containing two bottles of 60 capsules each. 

Import process:

1. Request submission for your medicine
   Patients or caregivers can send a request for the product by sharing prescription details and treatment requirements.
2. Submission of an application (Form 12A)
   Submit an application in Form 12A, along with a valid prescription from a Registered Medical Practitioner (RMP).
3. Verification of documents
   We verify the prescription and supporting medical documents to confirm eligibility for importing the drug in small quantities for personal medical use.
4. Permission to import
   Once approval is granted by the Drugs Controller General (India), the process of importing medicines begins as per the prescription.
5. Sourcing the medicine
   Our sourcing team connects with authorized global suppliers to find the best encorafenib price in India, thus making it convenient to easily import encorafenib in India, and ensure authenticity before finalizing the offer.
6. Delivery of the medicine
   After approval and confirmation, we coordinate logistics and ensure the safe, compliant, and timely delivery of the product to the patient’s location in India.

Documents Require: 

To enable the product’s import to India, patients need to provide:

1. A valid doctor’s prescription specifying the product name, dosage, treatment duration, and diagnosis.
2. Recent medical history and test reports (preferably from the last three months), including those confirming disease. 
3. Government-issued ID proof and proof of residence of the patient.
4. Import permit if applicable.  

Order is finalized only after submission of a valid prescription and necessary documents. Once the import permit is approved, the licensed supplier arranges shipment of Braftovi from the USA, Canada, Europe, or Australia, etc. 
With these steps, patients can import encorafenib India safely and legally. We make the medicines available in major Indian cities and source only from genuine international suppliers to ensure safety and authenticity. We ensure 100% transparency in pricing and supply is guaranteed. Prescriptions are dispensed and checked by registered pharmacists before delivery to patients.

Accessing Encorafenib (Braftovi) in India can be made seamless and compliant through the Named Patient Supply (NPS) Program. With proper guidance, patients can obtain this essential therapy safely and legally under the supervision of qualified healthcare professionals.

At 24/7 QualityMeds, we assist patients and caregivers through every stage—from documentation and regulatory approvals to sourcing from verified international suppliers. Our focus is on ensuring genuine medicines, transparent pricing, and reliable delivery across India. For the most updated details on Encorafenib pricing, availability, and import assistance in India, please contact our expert support team.